Membrane fusogenic nanoparticle‐based HLA ‐peptide‐addressing universal T cell receptor‐engineered T ( HAUL TCR‐T ) cell therapy in solid tumor

作者：Ruihan Xu, Qin Wang, Junmeng Zhu, Yuncheng Bei, Yanhong Chu, Zhichen Sun, Shiyao Du, Shujuan Zhou, Naiqing Ding, Fanyan Meng, Baorui Liu · 发表于：Bioengineering & Translational Medicine · 年份：2023 · DOI：10.1002/btm2.10585 · 被引用次数：8 · 研究领域：CAR-T cell therapy research、Nanowire Synthesis and Applications、Immunotherapy and Immune Responses

T cell receptor-engineered T (TCR-T) cell therapy has demonstrated therapeutic effects in basic research and clinical trials for treating solid tumors. Due to the peptide-dependent recognition and the human leukocyte antigen (HLA)-restriction, TCR-T cell therapy is generally custom designed to target individual antigens. The lack of suitable universal targets for tumor cells significantly limits its clinical applications. Establishing a universal TCR-T treatment strategy is of great significance. This study designed and evaluated the HLA-peptide-addressing universal (HAUL) TCR-T cell therapy based on HLA-peptide (pHLA) loaded membrance fusogenic deliver system. The pHLA-NP-based tumor cell membrane modification technology can transfer the pHLA onto the surface of tumor cells through membrane fusogenic nanoparticles. Then tumor cells are recognized and killed by TCR-T cells specifically. The HAUL TCR-T cell therapy technology is a universal technology that enables tumor cells to be identified and killed by specific TCR-T cells, regardless of the HLA typing of tumor cells.